Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis

Calcified Tissue International

Volumn 91, Issue 4, 2012, Pages 286-296

  Okazaki, Kyoko ^a   Yamaguchi, Toru ^a   Tanaka, Ken Ichiro ^a   Notsu, Masakazu ^a   Ogawa, Noriko ^a   Yano, Shozo ^a   Sugimoto, Toshitsugu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; Diabetes mellitus; Osteoblastic differentiation; Osterix; Stromal cell

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT 2; ADVANCED GLYCATION END PRODUCT 3; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; GLUCOSE; MESSENGER RNA; OSTEOCALCIN; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FRAGILITY FRACTURE; GENE EXPRESSION; MITOSIS INHIBITION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BONE MORPHOGENETIC PROTEIN 2; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MICE; OSTEOBLASTS; STROMAL CELLS; TRANSCRIPTION FACTORS;

EID: 84866009687     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9641-2     Document Type: Article

References (46)

1. Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a metaanalysis. Osteoporos Int 18:427-444 (Pubitemid 46354916)
2. Raskin P, Stevenson MR, Barilla DE, Pak CY (1978) The hypercalciuria of diabetes mellitus: its amelioration with insulin. Clin Endocrinol (Oxf) 9:329-335 (Pubitemid 9037305)
3. Ishida H, Cunningham NS, Henry HL, Norman AW (1988) The number of 1,25-dihydroxyvitamin D3 receptors is decreased in both intestine and kidney of genetically diabetic db/db mice. Endocrinology 122:2436-2443
4. Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E (1990) Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int 37:1522-1527 (Pubitemid 20198035)
5. Jehle PM, Jehle DR, Mohan S, Bohm BO (1998) Serum levels of insulin-like growth factor system components and relationship to bone metabolism in type 1 and type 2 diabetes mellitus patients. J Endocrinol 159:297-306 (Pubitemid 28520183)
6. Bouillon R, Bex M, Van Herck E, Laureys J, Dooms L, Lesaffre E, Ravussin E (1995) Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab 80:1194-1202
7. Botolin S, Faugere MC, Malluche H, Orth M, Meyer R, McCabe LR (2005) Increased bone adiposity and peroxisomal proliferatoractivated receptor-gamma2 expression in type I diabetic mice. Endocrinology 146:3622-3631 (Pubitemid 41058134)
8. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T (2009) Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int 85: 228-234
9. Brenner RE, Riemenschneider B, Blum W, Morike M, Teller WM, Pirsig W, Heinze E (1992) Defective stimulation of proliferation and collagen biosynthesis of human bone cells by serum from diabetic patients. Acta Endocrinol (Cph) 127:509-514 (Pubitemid 23029978)
10. Wang W, Zhang X, Zheng J, Yang J (2010) High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG-63 cells through cAMP/protein kinase A/extracellular signal-regulated kinase pathway. Mol Cell Biochem 338:115-122
11. Botolin S, McCabe LR (2006) Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 99:411-424 (Pubitemid 44435559)
12. Singh R, Barden A, Mori T, Beilin L (2001) Advanced glycation end-products: a review. Diabetol 44:129-146 (Pubitemid 32156196)
13. Vlassara H, Palace MR (2002) Diabetes and advanced glycation endproducts. J Intern Med 251:87-101 (Pubitemid 34146691)
14. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820 (Pubitemid 34000785)
15. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625 (Pubitemid 40770750)
16. Yamagishi S, Amano S, Inagaki Y, Okamoto T, Koga K, Sasaki N, Yamamoto H, Takeuchi M, Makita Z (2002) Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun 290:973-978 (Pubitemid 34687457)
17. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z (2002) Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in humancultured mesangial cells. J Biol Chem 277:20309-20315 (Pubitemid 34967325)
18. Sekido H, Suzuki T, Jomori T, Takeuchi M, Yabe-Nishimura C, Yagihashi S (2004) Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells. Biochem Biophys Res Commun 320:241-248 (Pubitemid 38781807)
19. Yamagishi S, Nakamura K, Inoue H (2005) Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients. Med Hypotheses 65:1013-1015 (Pubitemid 41425882)
20. Takagi M, Kasayama S, Yamamoto T, Motomura T, Hashimoto K, Yamamoto H, Sato B, Okada S, Kishimoto T (1997) Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res 12:439-446 (Pubitemid 27120481)
21. Yamamoto T, Ozono K, Miyauchi A, Kasayama S, Kojima Y, Shima M, Okada S (2001) Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 38:S161-S164 (Pubitemid 32927634)
22. Mercer N, Ahmed H, Etcheverry SB, Vasta GR, Cortizo AM (2007) Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells. Mol Cell Biochem 306:87-94 (Pubitemid 350001820)
23. Ding J, Nagai K, Woo JT (2003) Insulin-dependent adipogenesis in stromal ST2 cells derived from murine bone marrow. Biosci Biotechnol Biochem 67:314-321 (Pubitemid 39251984)
24. Otsuka E, Yamaguchi A, Hirose S, Hagiwara H (1999) Characterization of osteoblastic differentiation of stromal cell line ST2 that is induced by ascorbic acid. Am J Physiol 277:C132-C138 (Pubitemid 29352633)
25. Yamaguchi A, Ishizuya T, Kintou N, Wada Y, Katagiri T, Wozney JM, Rosen V, Yoshiki S (1996) Effects of BMP-2, BMP- 4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem Biophys Res Commun 220:366-371 (Pubitemid 26110126)
26. Sethe S, Scutt A, Stolzing A (2006) Aging of mesenchymal stem cells. Ageing Res Rev 5:91-116 (Pubitemid 43139669)
27. Kume S, Kato S, Yamagishi S, Inagaki Y, Ueda S, Arima N, Okawa T, Kojiro M, Nagata K (2005) Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. J Bone Miner Res 20:1647-1658 (Pubitemid 41243553)
28. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T (2007) The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 39:871-875
29. Lowry OH, Roberts NR, Wu ML, Hixon WS, Crawford EJ (1954) The quantitative histochemistry of brain II. Enzyme measurements. J Biol Chem 207:19-37
30. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2010) Fasudil hydrochloride induces osteoblastic differentiation of stromal cell lines, C3H10T1/2 and ST2, via bone morphogenetic protein-2 expression. Endocr J 57:415-421
31. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408 (Pubitemid 34164012)
32. Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N (1996) Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 11:931-937 (Pubitemid 26200043)
33. Stolzing A, Sellers D, Llewelyn O, Scutt A (2010) Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs 191:453-465
34. Cortizo AM, Lettieri MG, Barrio DA, Mercer N, Etcheverry SB, McCarthy AD (2003) Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem 250:1-10 (Pubitemid 37045717)
35. Komori T (2006) Regulation of osteoblast differentiation by transcription factors. J Cell Biochem 99:1233-1239
36. Nakashima K, Zhou X, Kunkel G, Zhang Z, Deng JM, Behringer RR, de Crombrugghe B (2002) The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108:17-29 (Pubitemid 34137009)
37. Fowlkes JL, Bunn RC, Liu L, Wahl EC, Coleman HN, Cockrell GE, Perrien DS, Lumpkin CK Jr, Thrailkill KM (2008) Runtrelated transcription factor 2 (RUNX2) and RUNX2-related osteogenic genes are down-regulated throughout osteogenesis in type 1 diabetes mellitus. Endocrinology 149:1697-1704 (Pubitemid 351468337)
38. Franke S, Siggelkow H, Wolf G, Hein G (2007) Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem 113:154-161 (Pubitemid 47547388)
39. Weil BR, Abarbanell AM, Herrmann JL, Wang Y, Meldrum DR (2009) High glucose concentration in cell culture medium does not acutely affect human mesenchymal stem cell growth factor production or proliferation. Am J Physiol Regul Integr Comp Physiol 296:R1735-R1743
40. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, Jilka RL (1999) Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 74:357-371 (Pubitemid 29344887)
41. Jeon MJ, Kim JA, Kwon SH, Kim SW, Park KS, Park SW, Kim SY, Shin CS (2003) Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem 278:23270-23277 (Pubitemid 36830140)
42. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, Terauchi Y, Harada Y, Azuma Y, Nakamura K, Kadowaki T, Kawaguchi H (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Investig 113:846-855 (Pubitemid 38544143)
43. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F (2003) High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18:960-974 (Pubitemid 37294932)
44. Kato M, Patel MS, Levasseur R, Lobov I, Chang BH, Glass DA 2nd, Hartmann C, Li L, Hwang TH, Brayton CF, Lang RA, Karsenty G, Chan L (2002) Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol 157:303-314 (Pubitemid 34839826)
45. Kang S, Bennett CN, Gerin I, Rapp LA, Hankenson KD, Macdougald OA (2007) Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancerbinding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem 282:14515-14524 (Pubitemid 47100486)
46. Takada I, Mihara M, Suzawa M, Ohtake F, Kobayashi S, Igarashi M, Youn MY, Takeyama K, Nakamura T, Mezaki Y, Takezawa S, Yogiashi Y, Kitagawa H, Yamada G, Takada S, Minami Y, Shibuya H, Matsumoto K, Kato S (2007) A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-gamma transactivation. Nat Cell Biol 9:1273-1285 (Pubitemid 350042359)